Group 1 - The core point of the article is that Regeneron Pharmaceuticals, Inc. has had its application for Garetosmab injection accepted by the National Medical Products Administration, with the acceptance date being January 15, 2026 [1] Group 2 - The application number for Garetosmab injection is JXSB2600006, categorized as a therapeutic biological product under a supplementary application registration classification 1 [1] - The company responsible for the application is Regeneron Pharmaceuticals, Inc. [1]